Besivance - Powerfully breaks the chain in pathogens of greater concern 1-3
  • Powerful and effective treatment
    of the pathogens of greater concern1-3
  • Provides long-lasting tear concentrations4-6
  • The first and only topical ophthalmic chlorofluoroquinolone1
    • BESIVANCE® is a dual-halogenated
      fluoroquinolone that provides potent
      inhibition of bacterial DNA replication1
  • Request Samples
Prescription pad

Besivance® (besifloxacin ophthalmic suspension) 0.6%, is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans *, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenza, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa *, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.


Besifloxacin is a dual halogenated
fluoroquinolone antibiotic that provides potent
inhibition of bacterial DNA replication.

Watch the video to the right to learn more »

Video thumbnail
Important Risk Information About BESIVANCE®
  • BESIVANCE® is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
  • As with other anti-infectives, prolonged use of BESIVANCE® may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE®
  • The most common adverse event reported in 2% of patients treated with BESIVANCE® was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE® occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • BESIVANCE® is not intended to be administered systemically. Quinolones administered systemically have been associated with hypersensitivity reactions, even following a single dose. Patients should be advised to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction.
  • Safety and effectiveness in infants below one year of age have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit,
or call 1-800-FDA-1088.

Please click here to view the BESIVANCE® full prescribing information.

References: 1. BESIVANCE Prescribing Information, April 2009. 2. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159-1169. 3. DeCory HH, Clinical Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% Against MRSA and MRSE, Annual Meeting of the Association for Research in Vision and Ophthalmology 2012; May 6-10, Fort Lauderdale, FL: 1 4. Data on File, CSR 424 2008, 424: 1-82, Bausch & Lomb Incorporated. 5. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25(4):335-343. 6. Haas W, Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clinical Ophthalmology 2011; 5: 1369-1379.

Legal Notice
©2014 Bausch & Lomb Incorporated. US/BES/13/0005 (1)

For product-related questions and concerns, call 1-800-323-0000
Bausch + Lomb Besivance besifloxacin opthalmic suspension, 0.6%

The information included on this website is intended for US healthcare professionals.

By clicking the button below, you acknowledge that you are a licensed US healthcare professional.

For eye care professionals